A study to assess the safety and tolerability of adavosertib for patients with advanced solid tumours

Trial Identifier: D601HC00009
Sponsor: AstraZeneca
NCTID:: NCT04949425
Start Date: September 2021
Primary Completion Date: April 2022
Study Completion Date: April 2022
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
English (UK) Translation
Spanish (Spain) Translation
Spanish (US) Translation

Trial Locations

Country Location
ES Barcelona, ES, 8023
ES Madrid, ES, 28029
ES Madrid, ES, 28041
ES Madrid, ES, 28031
ES Madrid, ES, 28040
ES Madrid, ES, 28034
ES Malaga, ES, 29010
ES Pozuelo de Alarcon, ES, 28223
GB London, GB, W12 0HS
GB Manchester, GB, M20 4BX
GB Wirral, GB, CH63 4JY
US, CT New Haven, CT, US, 06510
US, GA Newnan, GA, US, 30265
US, MI Farmington Hills, MI, US, 48334
US, NH Lebanon, NH, US, 03756
US, OH Cincinnati, OH, US, 45267
US, OR Portland, OR, US, 97213
US, TX Austin, TX, US, 78758
US, TX Dallas, TX, US, 75230